Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach

Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease

(2022) Alicia Garrido et al.   MOVEMENT DISORDERS

Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease

(2022) Jasmin Galper et al.   BRAIN

Role of Lysosomal Gene Variants in Modulating GBA ‐Associated Parkinson's Disease Risk

(2022) Letizia Straniero et al.   MOVEMENT DISORDERS

Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review

(2022) Massimo Filippi et al.   MOVEMENT DISORDERS

Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease

(2022) Antonio Sánchez-Rodríguez et al.   PARKINSONISM & RELATED DISORDERS

Genetic heterogeneity on sleep disorders in Parkinson’s disease: a systematic review and meta-analysis

(2022) Jingxuan Huang et al.   Translational Neurodegeneration

Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers

(2022) Amgad Droby et al.   npj Parkinsons Disease

Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease

(2022) Giulietta Maria Riboldi et al.   Molecular Neurodegeneration

A 10‐Year Community‐Based Study of Leucine‐Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease

(2022) Pei Wang et al.   MOVEMENT DISORDERS

Who to Enroll in Parkinson Disease Prevention Trials?

(2022) Kellyann Niotis et al.   NEUROLOGY

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease

(2022) Laura J. Smith et al.   Frontiers in Neurology

The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines

(2022) Laura J Smith et al.   HUMAN MOLECULAR GENETICS

Biochemical markers for severity and risk in GBA and LRRK2 Parkinson’s disease

(2021) Avner Thaler et al.   JOURNAL OF NEUROLOGY

Functional Connectivity Analysis in Heterozygous Glucocerebrosidase Mutation Carriers

(2021) Mine Sezgin et al.   Journal of Parkinsons Disease

Putative second hit rare genetic variants in families with seemingly GBA-associated Parkinson’s disease

(2021) Muhammad Aslam et al.   npj Genomic Medicine

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers With and Without Parkinson Disease

(2021) Jasmin Galper et al.   MOVEMENT DISORDERS

Profiling the Biochemical Signature of GBA‐Related Parkinson's Disease in Peripheral Blood Mononuclear Cells

(2021) Micol Avenali et al.   MOVEMENT DISORDERS

Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers

(2021) Eileen E. Moran et al.   Frontiers in Neurology

Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease

(2021) Dongbing Lai et al.   ANNALS OF NEUROLOGY

Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers

(2021) Avner Thaler et al.   Journal of Parkinsons Disease

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression

(2021) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity

(2021) Nurit Omer et al.   MOVEMENT DISORDERS

Increased α‐Synuclein Level in CD45 + Blood Cells in Asymptomatic Carriers of GBA Mutations

(2021) Anton Emelyanov et al.   MOVEMENT DISORDERS

Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease

(2021) Matthew Surface et al.   MOVEMENT DISORDERS

Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers

(2021) Ioanna Pachi et al.   PARKINSONISM & RELATED DISORDERS

Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease

(2021) Myung Jun Lee et al.   npj Parkinsons Disease

Longitudinal Positron Emission Tomography of Dopamine Synthesis in Subjects with GBA1 Mutations

(2020) Grisel Lopez et al.   ANNALS OF NEUROLOGY

Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score

(2020) Hirotaka Iwaki et al.   MOVEMENT DISORDERS

In vivo signatures of neurodegeneration in isolated rapid eye movement behaviour disorder

(2020) Giulia Carli et al.   EUROPEAN JOURNAL OF NEUROLOGY

Age at Onset of Parkinson’s Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations

(2020) Gilad Yahalom et al.   Journal of Parkinsons Disease

Leucine Rich Repeat Kinase 2 and Innate Immunity

(2020) Diba Ahmadi Rastegar et al.   Frontiers in Neuroscience

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers

(2020) Nour K. Majbour et al.   Translational Neurodegeneration

Nonsteroidal Anti‐Inflammatory Use and LRRK2 Parkinson's Disease Penetrance

(2020) Marta San Luciano et al.   MOVEMENT DISORDERS

GBA ‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort

(2020) Simona Petrucci et al.   MOVEMENT DISORDERS

GBA variants in REM sleep behavior disorder: a multicenter study

(2020) Lynne Krohn et al.   NEUROLOGY

Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease

(2020) Avner Thaler et al.   Scientific Reports

Current and projected future economic burden of Parkinson’s disease in the U.S.

(2020) Wenya Yang et al.   npj Parkinsons Disease

Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study

(2020) Jacob Horsager et al.   BRAIN

GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes

(2020) Andrea Greuel et al.   MOVEMENT DISORDERS

Age at Onset of LRRK2 p. Gly2019Ser Is Related to Environmental and Lifestyle Factors

(2020) Theresa Lüth et al.   MOVEMENT DISORDERS

If LRRK2 Set the Fire, Can Nonsteroidal Anti‐inflammatory Drugs Wet the Flames?

(2020) Grace F. Crotty et al.   MOVEMENT DISORDERS

Association of caffeine and related analytes with resistance to Parkinson’s disease among LRRK2 mutation carriers: A metabolomic study

(2020) Grace F Crotty et al.   NEUROLOGY

Brain Microglial Activation Increased in Glucocerebrosidase ( GBA ) Mutation Carriers without Parkinson's disease

(2020) Stephen Mullin et al.   MOVEMENT DISORDERS

Higher urate in LRRK2 mutation carriers resistant to Parkinson disease

(2019) Rachit Bakshi et al.   ANNALS OF NEUROLOGY

α ‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK 2‐linked Parkinson's disease

(2019) Alicia Garrido et al.   Annals of Clinical and Translational Neurology

GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches

(2019) Giulietta M. Riboldi et al.   Cells

Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study

(2019) Micol Avenali et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Evolution and clustering of prodromal parkinsonian features in GBA1 carriers

(2019) Stephen Mullin et al.   MOVEMENT DISORDERS

Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development

(2019) Roy N. Alcalay et al.   MOVEMENT DISORDERS

Update of the MDS research criteria for prodromal Parkinson's disease

(2019) Sebastian Heinzel et al.   MOVEMENT DISORDERS

Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia

(2019) Cornelis Blauwendraat et al.   BRAIN

LRRK2 and GBA Variants Exert Distinct Influences on Parkinson’s Disease-Specific Metabolic Networks

(2019) Katharina A Schindlbeck et al.   CEREBRAL CORTEX

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

(2019) Tanya Simuni et al.   LANCET NEUROLOGY

Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson’s Disease and Their First-Degree Unaffected Relatives

(2018) Avner Thaler et al.   BRAIN TOPOGRAPHY

Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study

(2018) Tiago A. Mestre et al.   MOVEMENT DISORDERS

Application of the Movement Disorder Society prodromal criteria in healthy G2019S -LRRK2 carriers

(2018) Anat Mirelman et al.   MOVEMENT DISORDERS

Progression in the LRRK2-Associated Parkinson Disease Population

(2018) Rachel Saunders-Pullman et al.   JAMA Neurology

The Parkinson Pandemic—A Call to Action

(2018) E. Ray Dorsey et al.   JAMA Neurology

Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson's Disease: A Meta-Analysis

(2018) Yuan Zhang et al.   Frontiers in Molecular Neuroscience

Cognition among individuals along a spectrum of increased risk for Parkinson’s disease

(2018) Lana M. Chahine et al.   PLoS One

The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies

(2017) Claustre Pont-Sunyer et al.   MOVEMENT DISORDERS

Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers

(2017) Eileen E. Moran et al.   NEUROBIOLOGY OF AGING

Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease

(2017) S. Pchelina et al.   NEUROSCIENCE LETTERS

Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder

(2017) Thomas R Barber et al.   SLEEP

Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder

(2017) Thomas R Barber et al.   SLEEP

Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's

(2016) Ganqiang Liu et al.   ANNALS OF NEUROLOGY

A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers

(2016) Noa Bregman et al.   Brain Structure & Function

Prodromal Clinical Markers of Parkinson disease in Gaucher Disease Individuals

(2016) Emilia M. Gatto et al.   EUROPEAN NEUROLOGY

The epidemiology of Parkinson's disease: risk factors and prevention

(2016) Alberto Ascherio et al.   LANCET NEUROLOGY

Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers

(2016) Nicolas Dzamko et al.   MOVEMENT DISORDERS

Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers

(2016) Dolores Vilas et al.   MOVEMENT DISORDERS

Arm swing as a potential new prodromal marker of Parkinson's disease

(2016) Anat Mirelman et al.   MOVEMENT DISORDERS

Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in theLRRK2gene

(2015) Anat Mirelman et al.   MOVEMENT DISORDERS

Age-specific penetrance ofLRRK2G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium

(2015) Karen Marder et al.   NEUROLOGY

Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease

(2015) Lorraine V. Kalia et al.   JAMA Neurology

Evolution of Prodromal Clinical Markers of Parkinson Disease in aGBAMutation–Positive Cohort

(2015) Michelle Beavan et al.   JAMA Neurology

Parkinson disease phenotype in Ashkenazi jews with and withoutLRRK2G2019S mutations

(2013) Roy N. Alcalay et al.   MOVEMENT DISORDERS

Hyposmia and cognitive impairment in Gaucher disease patients and carriers

(2012) Alisdair McNeill et al.   MOVEMENT DISORDERS

Gait alterations in healthy carriers of the LRRK2 G2019S mutation

(2011) Anat Mirelman et al.   ANNALS OF NEUROLOGY

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

(2009) Juliane Neumann et al.   BRAIN

Neuropathology of Parkinson's disease with the R1441G mutation inLRRK2

(2009) José-Félix Martí-Massó et al.   MOVEMENT DISORDERS

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

(2008) Daniel G Healy et al.   LANCET NEUROLOGY